目的: 调查了解医疗机构实施药品价格监测管理的现状,了解医务人员对“红黄绿”监测等药品价格监管措施的认知及态度,为规范和完善药品价格监测管理提供参考。方法: 对样本医疗机构开展问卷调查,对相关人员进行半结构化访谈,在描述性统计分析基础上对不同等级医疗机构实施差异等进行推论统计学分析。结果: 问卷调查共收回25家医疗机构370份医护药受访者有效问卷。76.8%受访者认为当前的药品价格呈现稳定至下降趋势,降价幅度方面三级医疗机构的感知大于二级医疗机构(P=0.034)和二级以下医疗机构(P=0.005);医务人员普遍认为药品价格监管政策对其处方行为产生一定影响,主要影响政策有“药占比”(n=323,87.3%)、“集采”(n=294,79.5%)和“基药”(n=294,79.5%);医务人员开具处方时优先考虑因素有“临床效果”(n=178,48.1%)和“药品价格”(n=147,39.7%);访谈显示医疗机构药品管理人员对“红黄绿”监测规范的理解尚不到位,部分医疗机构未建立完整透明的内部管理制度。结论: 药品价格控制政策实施有效,维护了药品市场的合理价格并促进医疗机构合理用药。但不同药品监管政策的冗杂对医生处方行为有一定限制影响,建议不同政策间应做好落地协调与细化,医疗机构建立透明价格监测体系,加强医务人员培训。
Abstract
Objective: To investigate the current situation of the medical institutions to implement the drug price monitoring and management, and to understand the awareness and attitude of medical staffs towards Red-Yellow-Green monitoring and other pharmaceutical price regulation measures, in order to provide reference for standardizing and improving drug price monitoring and management. Methods: A questionnaire survey was conducted in the sample medical institutions, and semi-structured interviews were conducted with relevant personnel. On the basis of descriptive statistical analysis, inferential statistical analysis was conducted on the implementation differences of medical institutions at different levels. Results: A total of 370 valid questionnaires were collected from 25 medical institutions. Among which, 76.8% of the respondents believed that the current drug prices showed a stable to declining trend, and the perception of the price reduction rate of tertiary medical institutions was greater than that of secondary medical institutions (P=0.034) and sub-secondary medical institutions (P=0.005). Medical staff generally believed that the drug price regulation policy had a certain impact on their prescription behavior, mainly affecting the proportion of drug proportion (n=323, 87.3%), centralized procurement (n=294, 79.5%) and basic drugs (n=294, 79.5%). Clinical effect (n=178, 48.1%) and drug price (n=147, 39.7%) were the priority factors for medical staff to prescribe. The interviews showed that the drug management personnel of medical institutions did not have a proper understanding of the Red-Yellow-Green price monitoring policy, and some medical institutions had not established a complete and transparent internal management system. Conclusion: The drug price control policy has been effectively implemented, maintaining reasonable prices in the drug market and promoting rational drug use in medical institutions. However, the complexity of different drug regulatory policies has a certain limiting effect on doctors' prescribing behavior. It is suggested that different policies should be well coordinated and refined, medical institutions should establish a transparent price monitoring system, and strengthen the training of medical staff .
关键词
药品价格监测 /
问卷调查 /
医疗机构 /
“红黄绿”药品价格监测政策 /
处方行为
{{custom_keyword}} /
Key words
drug price monitoring /
questionnaire survey /
medical institution /
Red-Yellow-Green price monitoring policy /
prescribing behavior
{{custom_keyword}} /
中图分类号:
R95
{{custom_clc.code}}
({{custom_clc.text}})
{{custom_sec.title}}
{{custom_sec.title}}
{{custom_sec.content}}
参考文献
[1] 国家发展和改革委员会,国家卫生和计划生育委员会,人力资源社会保障部,等. 关于印发推进药品价格改革意见的通知[EB/OL].(2015-05-04)[2024-04-22]. http://www.nhc.gov.cn/yaozs/s3573/201505/fa53ac96f6094090bfe2663fb7c69bf0.shtml.
[2] 王竞,周文犁,周延安,等. 我国药品价格管理研究[J]. 中国药师,2018,21(12): 2196-2200.
[3] 国家医疗保障局. 关于印发《关于做好当前药品价格管理工作的意见》的通知[EB/OL].(2019-11-26)[2024-05-21].https://www.gov.cn/zhengce/zhengceku/2019-12/08/content_5562279.htm.
[4] 新华社. 中共中央国务院关于深化医疗保障制度改革的意见[EB/OL].(2020-02-25)[2024-05-18]. https://www.gov.cn/zhengce/2020-03/05/content_5487407.htm.
[5] 胡善联. 中国医保药品价格谈判回顾和展望[J]. 卫生经济研究,2024,41(1):9-13.
[6] 翁冰冰,蒋虹丽,郭元,等. 药品集中带量采购的地方实践与探索[J]. 中国卫生资源,2022,25(6):756-764.
[7] 郑朝臣,路云,常峰,等. 我国地方区域性药品挂网采购的做法分析与思考[J]. 中国药房,2023,34(3):263-268.
[8] 江苏省医疗保障局. 江苏省医疗保障局关于推进阳光挂网药品价格治理工作的通知[EB/OL].(2024-04-09)[2024-05-20]. https://ybj.jiangsu.gov.cn/art/2024/4/9/art_74038_11213305.html.
[9] 青海省医疗保障局. 关于开展挂网药品和医用耗材价格监测治理工作的通知[EB/OL].(2022-03-14)[2024-05-21]. https://ybj.qinghai.gov.cn/2022-03/25/c_1211621691.htm.
[10] 章程,龚波. 上海市优化药品挂网议价采购监管机制的实践及成效[J]. 中国医疗保险, 2021(8):46-48.
[11] 海南省医疗保障局. 关于印发《海南省医药招采和价格监测管理暂行办法》的通知[EB/OL].(2021-05-14)[2024-05-21]. https://ybj.hainan.gov.cn/xxgk/tzgg/202106/t20210623_2998759.html.
[12] 四川省药械招标采购服务中心.《四川省药械集中采购和医药价格监管平台挂网药品价格监测规范》的通知[EB/OL].(2021-08-13)[2024-05-21]. https://www.scyxzbcg.cn/detail.html?infoId=21450&CatalogId=26.
[13] 刘嘉楠. 药占比与医疗费用控制的关系及其调控政策研究[D]. 大连理工大学,2021.
[14] 闫抗抗,杨世民,方宇,等. 377名基层医师对国家基本药物制度认知情况的KAP调查[J]. 中国药房,2010,21(44):4209-4212.
[15] 张蔓,王一彪,左根永. 我国医疗机构药师对医改政策的认知调查[J]. 医学与社会,2019,32(11):93-96.
[16] 颜伊琪,汪皖青,潘杰,等. 苏州地区14家医疗机构医师对国家药品集中采购政策的认知现状及药学需求调查研究[J]. 中国现代应用药学,2023,40(9):1240-1247.
[17] 杨春艳,刘剑敏,张新平. 医疗机构药品使用信息透明的内涵与概念框架[J]. 医学与社会,2016,29(4):11-13.
[18] 胡善联. 国内外药品价格和费用控制政策的比较研究[J]. 中国药房,2013,24(44): 4129-4132.
[19] 彭婧. 世界经济合作组织成员国药品费用控制策略及对我国的启示[J]. 安徽医药,2018,22(5):807-810.
[20] 李佳芮,杨风,李文芬,等. 关于国内外医疗机构腐败问题的研究综述[J]. 中国卫生事业管理,2022,39(4):271-274.
[21] 訾晨晨,张丹,孙丽丹,等. 关于全面实施药品挂网公开议价采购的工作模式探讨[J]. 中国农村卫生,2022,14(4):69-71.
[22] 樊宏,王雅芸,魏良敏,等. 基于主成分分析以及模糊综合评判法的医生处方行为影响因素分析[J]. 中国卫生事业管理,2019,36(7):481-484,518.
[23] 徐灿. 医疗服务收费中“药占比”管控政策研究[D]. 咸阳:西北农林科技大学,2021.
{{custom_fnGroup.title_cn}}
脚注
{{custom_fn.content}}